Skip to content

About
Science
Pipeline
Therapeutic Areas
- Dry AMD
- Dry Eye Disease
News

Reimagining pathways to ocular health

Pipeline
Risuteganib
ALG-1007
Clinical Trials

On the cutting-edge of science with a new mechanism of action

Allegro Ophthalmics - From Theory to Therapy

Setting the pace in ocular care
Read More >

Allegro Ophthalmics LLC
31473 Rancho Viejo Road, Suite 207
San Juan Capistrano, CA 92675, USA
Phone: +1 949.940.8130
Email: info@allegroeye.com

RECENT NEWS

Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of Intermediate Dry AMD
September 25, 2023

Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD
April 13, 2023

About
Science
Pipeline
Therapeutic Areas
News
Careers
Contact Us

© 2024 Allegro Ophthalmics, LLC. All rights reserved. | Privacy Policy | Terms of Use